Revolution Medicines Inc (RVMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Revolution Medicines Inc (RVMD) has a cash flow conversion efficiency ratio of -0.285x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-741.48 Million) by net assets ($2.61 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Revolution Medicines Inc (RVMD) total market value for the company's overall valuation and market capitalisation.
Revolution Medicines Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Revolution Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Revolution Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revolution Medicines Inc ranked by their cash flow conversion efficiency. See Revolution Medicines Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KB Financial Group
KO:105560
|
0.025x |
|
Infosys Limited
F:IOY
|
0.095x |
|
Adani Power Limited
NSE:ADANIPOWER
|
0.225x |
|
WEG S.A.
SA:WEGE3
|
0.059x |
|
ASE TECHN.HLDG.CO.LTD.
F:2DQ
|
N/A |
|
Entergy Corporation
NYSE:ETR
|
0.126x |
|
RWE Aktiengesellschaft
F:RWEA
|
0.095x |
|
Argen-X
F:1AE
|
N/A |
Annual Cash Flow Conversion Efficiency for Revolution Medicines Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Revolution Medicines Inc from 2017 to 2025. View Revolution Medicines Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.63 Billion | $-897.74 Million | -0.550x | -123.63% |
| 2024-12-31 | $2.27 Billion | $-557.44 Million | -0.246x | -28.19% |
| 2023-12-31 | $1.83 Billion | $-350.57 Million | -0.192x | +41.38% |
| 2022-12-31 | $685.19 Million | $-224.40 Million | -0.328x | -34.08% |
| 2021-12-31 | $602.57 Million | $-147.18 Million | -0.244x | -15.87% |
| 2020-12-31 | $474.68 Million | $-100.06 Million | -0.211x | +35.19% |
| 2019-12-31 | $152.53 Million | $-49.62 Million | -0.325x | -2691.99% |
| 2018-12-31 | $96.66 Million | $1.21 Million | 0.013x | +100.23% |
| 2017-12-31 | $4.53 Million | $-25.15 Million | -5.550x | -- |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more